NCT07554339
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 23 versions: 23 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 115 → 119 locations
- Trial sites expanded: 107 → 115 locations
- Minor Study sites: 107 to 115
- Minor Trial sites expanded: 103 → 107 locations
- Minor Trial sites expanded: 98 → 103 locations
- Minor Trial sites expanded: 95 → 98 locations
- Minor Trial sites expanded: 91 → 95 locations
- Minor Trial sites expanded: 84 → 91 locations
- Trial sites expanded: 80 → 84 locations
- Minor Study sites: 80 to 84
- Notable Eligibility criteria expanded, about 20 words
- Trial sites expanded: 73 → 80 locations
- Secondary endpoints: details revised at 7 of 9 entries
- Minor Trial sites expanded: 65 → 73 locationsv14
- Minor Study sites: 63 to 65v13
- Minor Trial sites expanded: 59 → 63 locationsv12
- Minor Trial sites expanded: 56 → 59 locationsv11
- Minor Trial sites expanded: 53 → 56 locationsv10
- Minor Study sites: 52 to 53v9
- Minor Study sites: 50 to 52v8
- Minor Trial sites expanded: 35 → 50 locationsv7
- Minor Study sites: 33 to 35v6
- Minor Trial sites expanded: 25 → 33 locations
- Trial sites expanded: 16 → 25 locations
- Minor Study sites: 16 to 25v4
- Minor Trial sites expanded: 5 → 16 locations
- Start date changed from estimate of Jun 5, 2026 to Jun 18, 2026
- Notable Recruitment opened
- Trial sites expanded: 0 → 5 locations
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression-Free Survival (PFS)
Timeframe: Up to approximately 6 years
Secondary (9)
Overall Survival (OS)
Number of Participants Who Experience an Adverse Events (AEs)
Number of Participants Who Discontinue Study Treatment Due to an AE
Objective Response Rate (ORR)
Duration of Response (DOR)
Show 4 moreShow less
Distant Metastasis-Free Survival (DMFS)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/Quality of Life (QoL) (Items 29 & 30) Combined Score
Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Combined Score
Change from Baseline in Role Functioning (EORTC QLQ-C30 Items 6 & 7) Combined Score
Arms and interventions
Calderasib + DurvalumabExperimental
Participants will receive calderasib and durvalumab.
Placebo + DurvalumabActive comparator
Participants will receive placebo to calderasib and durvalumab.
Drugs: Calderasib
Biologicals: Durvalumab
Other: Placebo to MK-1084
Sites
119 sites in 18 countries
China 28, Ukraine 14, Turkey (Türkiye) 9, United States 8, Spain 7, Argentina 6, Japan 6, South Korea 6, Brazil 5, Greece 5, Taiwan 5, Australia 4, Italy 4, Netherlands 4, Germany 3, France 2, United Kingdom 2, Poland 1